This narrative review evaluates 25 years of evidence on lithium as a disease-modifying agent in mild cognitive impairment (MCI) and Alzheimer disease (AD), covering preclinical, epidemiological, neuroimaging, and early randomized clinical trial data.
Converging evidence shows low-dose lithium (~0.3 mM, well below standard psychiatric doses of 0.6–1.0 mM) exerts neuroprotective effects via GSK-3β inhibition, BDNF signaling, Bcl-2 induction, and mitochondrial stabilization; early RCTs in MCI suggest cognitive stabilization and favorable tau biomarker changes; epidemiological studies link cumulative lithium exposure to reduced dementia risk.
- Early RCT data in MCI are preliminary and not yet from large, definitive trials. - The 'repletion hypothesis' (lithium as a physiological trace element) lacks independent replication. - Long-term safety data for low-dose lithium orotate specifically (vs. carbonate) in older/cognitively impaired populations are limited.
Low-dose lithium orotate may be a safe, affordable option worth studying to slow MCI progression, but clinicians should await results from prospective trials before routine use. The more favorable side-effect profile at low doses compared to standard lithium carbonate makes it a compelling candidate for formal evaluation.
Explore related topics
